The evolution of Ki-67 and breast carcinoma: past observations, present directions, and future considerations
BS Finkelman, H Zhang, DG Hicks, BM Turner - Cancers, 2023 - mdpi.com
Simple Summary Cellular proliferation is a central determinant of breast cancer recurrence
risk and response to chemotherapy. The discovery of the Ki-67 antibody by Dr. Johannes …
risk and response to chemotherapy. The discovery of the Ki-67 antibody by Dr. Johannes …
Post-neoadjuvant treatment and the management of residual disease in breast cancer: state of the art and perspectives
R Caparica, M Lambertini, N Pondé… - … in medical oncology, 2019 - journals.sagepub.com
Achieving a pathologic complete response after neoadjuvant treatment is associated with
improved prognosis in breast cancer. The CREATE-X trial demonstrated a significant …
improved prognosis in breast cancer. The CREATE-X trial demonstrated a significant …
[HTML][HTML] CD8+ cytotoxic and FoxP3+ regulatory T lymphocytes serve as prognostic factors in breast cancer
GL Peng, L Li, YW Guo, P Yu, XJ Yin… - American journal of …, 2019 - ncbi.nlm.nih.gov
Background: There is conflicting evidence regarding the prognostic value of cytotoxic T cell
infiltration in breast cancer. The aims of this study were to detect the expression levels and …
infiltration in breast cancer. The aims of this study were to detect the expression levels and …
15-Gene Expression Profile and PRAME as Integrated Prognostic Test for Uveal Melanoma: First Report of Collaborative Ocular Oncology Group Study No. 2 …
JW Harbour, ZM Correa, AC Schefler… - Journal of clinical …, 2024 - ascopubs.org
PURPOSE Validated and accurate prognostic testing is critical for precision medicine in
uveal melanoma (UM). Our aims were to (1) prospectively validate an integrated prognostic …
uveal melanoma (UM). Our aims were to (1) prospectively validate an integrated prognostic …
Mucin-microbiome signatures shape the tumor microenvironment in gastric cancer
B Oosterlinck, H Ceuleers, W Arras, JG De Man… - Microbiome, 2023 - Springer
Background and aims We aimed to identify mucin-microbiome signatures shaping the tumor
microenvironment in gastric adenocarcinomas and clinical outcomes. Methods We …
microenvironment in gastric adenocarcinomas and clinical outcomes. Methods We …
Assessment of estrogen receptor low positive status in breast cancer: Implications for pathologists and oncologists
Estrogen receptor (ER) status assessment by immunohistochemistry (IHC) is the gold
standard test for the identification of patients with breast cancer who may benefit from …
standard test for the identification of patients with breast cancer who may benefit from …
Evaluation of DNA and RNA quality from archival formalin‐fixed paraffin‐embedded tissue for next‐generation sequencing–Retrospective study in Japanese single …
T Fujii, T Uchiyama, M Matsuoka, T Myojin… - Pathology …, 2020 - Wiley Online Library
Genetic analysis on formalin‐fixed paraffin‐embedded (FFPE) tissue specimens has
become a mainstream method, from conventional direct sequencing to comprehensive …
become a mainstream method, from conventional direct sequencing to comprehensive …
Ki‐67 Expression by Immunohistochemistry and Quantitative Real‐Time Polymerase Chain Reaction as Predictor of Clinical Response to Neoadjuvant Chemotherapy …
P Prihantono, M Hatta, C Binekada… - Journal of …, 2017 - Wiley Online Library
Background. Chemotherapy has become a standard of treatment in managing breast
cancer. To achieve proper treatment for the right patients, the predictive marker is needed. Ki …
cancer. To achieve proper treatment for the right patients, the predictive marker is needed. Ki …
The use of automated Ki67 analysis to predict Oncotype DX risk-of-recurrence categories in early-stage breast cancer
Ki67 is a commonly used marker of cancer cell proliferation, and has significant prognostic
value in breast cancer. In spite of its clinical importance, assessment of Ki67 remains a …
value in breast cancer. In spite of its clinical importance, assessment of Ki67 remains a …
Phase 2 study of anastrozole in recurrent estrogen (ER)/progesterone (PR) positive endometrial cancer: The PARAGON trial–ANZGOG 0903
L Mileshkin, R Edmondson, RL O'Connell… - Gynecologic …, 2019 - Elsevier
Background The clinical benefit rate with aromatase inhibitors and the impact of treatment
on quality of life (QOL) in endometrial cancer is unclear. We report the results of a phase 2 …
on quality of life (QOL) in endometrial cancer is unclear. We report the results of a phase 2 …